- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Scott S. Tykodi, MD, PhD | Authors
Cytoreductive Nephrectomies for Renal Cell Carcinoma
May 19, 2022
Drs Thomas Hutson and Scott Tykodi explain when to consider a debulking surgery for patients with renal cell carcinoma.
Sequencing Strategies for Renal Cell Carcinoma Treatment Regimens
May 12, 2022
A look at how to best sequence therapies for renal cell carcinoma from the front-line setting on.
Advice for Community Oncologists Treating Renal Cell Carcinoma
May 09, 2022
Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.
The Influence of Risk Category Stratification Algorithms on CLEAR Trial Data
March 31, 2022
Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.
A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
March 31, 2022
Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.
Scott Tykodi, MD, PhD, on Takeaways from KEYNOTE-427 in Renal Cell Carcinoma
July 24, 2020
The Seattle Cancer Care Alliance expert discusses key takeaways from cohort a of the KEYTRUDA-427 study, evaluating pembrolizumab monotherapy in patients with clear cell renal cell carcinoma.
Scott Tykodi, MD, PhD, Discusses Biomarker Detection, Analysis in RCC
July 13, 2020
The Seattle Cancer Care Alliance Expert offered background on cohort A of the KEYNOTE-427 trial.
Scott Tykodi, MD, PhD, on Results from the KEYNOTE-427 Trial
June 21, 2020
The Seattle Cancer Care Alliance Expert offered background on the first-line use of pembrolizumab monotherapy in advanced clear cell renal cell carcinoma.
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
February 15, 2015
In this article, we summarize the systemic therapies now available for melanoma, with a focus on the recently approved agents for cutaneous melanoma; discuss important considerations in selecting a treatment from the available options; and highlight some of the promising investigational approaches for this disease.
Treatment of Metastatic Melanoma: An Overview
May 12, 2009
Metastatic melanoma continues to be a challenging disease to treat, with an estimated 8,420 related deaths in the United States in 2008.[1] The 10- year survival rate for patients with metastatic melanoma is less than 10%.[2] More than 3 decades after its initial approval by the US Food and Drug Administration (FDA) in 1975, dacarbazine continues to be the standard of care for most patients with this disease. High-dose interleukin-2 (HD IL-2 [Proleukin]), approved by the FDA in 1998 for metastatic melanoma, benefits a small subset of patients.